Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

NCT02436707 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02436707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02436707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 27, 2015
Completion date
December 31, 2026
Enrollment
129 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma